Safety and Efficacy Evaluation of Recombinant Marek's Disease Virus with REV-LTR

文献类型： 外文期刊

第一作者： Song, Cuiping

作者： Song, Cuiping;Yang, Yang;Hu, Jing;Yu, Shengqing;Sun, Yingjie;Qiu, Xvsheng;Tan, Lei;Meng, Chunchun;Liao, Ying;Liu, Weiwei;Ding, Chan

作者机构：

关键词： safety; efficacy; recombinant Marek's disease virus; REV-LTR

期刊名称：VACCINES （ 影响因子：4.422； 五年影响因子：5.513 ）

ISSN：

年卷期： 2020 年 8 卷 3 期

页码：

收录情况： SCI

摘要： Recently, chickens vaccinated with the CVI988/Rispens vaccine showed increased tumor incidence. Moreover, many strains of Marek's disease virus (MDV) that were naturally integrated with the long terminal repeat (LTR) of the avian reticuloendotheliosis virus (REV) have been isolated, which means it is necessary to develop a new vaccine. In this study, two LTR sequences were inserted into Rispens to construct a recombinant MDV (rMDV). Then, the safety and efficacy of rMDV were evaluated separately in chickens. The growth rate curves showed that the insertion of REV-LTR into MDV enabled a faster replication in vitro than Rispens. Chickens immunized with high or repeated dose rMDV had no MD clinical signs. Further, no tumor, tissue lesions, or evident pathological changes were observed in the chicken organs. Polymerase chain reaction (PCR) and virus isolation revealed that rMDV had the ability to spread horizontally to non-immunized chickens and had no impact on the environment. After five passages in chickens, there were no obvious lesions, and the LTR insertion was stable. There were also no deletions or mutations, which indicates that rMDV is safe in chickens. In addition, rMDV has an advantage over Rispens against vvMDV Md5 at low doses. All results demonstrate that the transgenic strain of rMDV with REV-LTR can be used as a live attenuated vaccine candidate.

分类号：

  • 相关文献
作者其他论文 更多>>

微信小程序